Both in tumour models (Pan et al, 2002, 2003a, 2003b; Hassouneh et al, 2007) and in in vivo angiogenesis models, such as the Matrigel plug model (Juarez et al, 2006), ATN-224 has a strong antiangiogenic activity, and we wished to establish a relationship between the dose needed to inhibit angiogenesis and that needed to inhibit SOD activity in blood cells. This evidence concerns the gene SOD1 and neoplasm.